For attending this session, you can claim 1.5 EACCME credits
After this session, the attendees should be able to:
- Discuss historical outcomes in patients undergoing liver transplantation for intrahepatic cholangiocarcinoma and metastatic neuroendocrine cancer and risk factors associated with poorer outcomes
- Examine new concepts in the use of neoadjuvant therapy, optimizing staging, timing and management of patients with intrahepatic cholangiocarcinoma and metastatic neuroendocrine tumors to the liver in consideration for liver transplantation
- Understand the use of cell free DNA in managing patients with HCC before and after liver transplantation for hepatocellular carcinoma
| Prof. John J Fung, United States | Nicolas Jarufe Cassis, Chile | Dr. Javier C Lendoire, Argentina |
